Daphna Nesselroth1, Ronit Gilad2, Montaser Namneh3, Sarit Avishay4, Anda Eilam5. 1. Sackler Medical School, Tel-Aviv University, Israel. 2. Neurological department, Kaplan Medical Center, Rechovot, Israel; Hebrew university, Jerusalem, Israel. 3. Neurological department, Kaplan Medical Center, Rechovot, Israel. 4. Management department, Kaplan Medical Center, Rechovot, Israel. 5. Neurological department, Kaplan Medical Center, Rechovot, Israel. Electronic address: andail@clalit.org.il.
Abstract
PURPOSE: Post stroke seizures are a complication that occur in 5-20% of acute ischemic stroke (AIS) patients, cause a reduction in quality of life and a greater burden on the health system. There is not enough data regarding an association between today's standard of care treatment in AIS: recombinant tissue plasminogen activator (r-tPA) and the risk for post stroke seizures. Our aim in this work is to reveal such a connection. METHOD: A non-randomized retrospective cohort-controlled study of 234 patients, who were hospitalized with acute ischemic stroke at Kaplan Medical Center in the years 2009-2015 and were divided into two different treatment groups: r-tPA and antiaggregant therapy(n = 141) and antiaggregant therapy only (n = 95) was conducted by us. Information regarding demographics, medical history, nature of the event, including NIHSS values on admission, discharge, and post stroke seizures, were obtained for each group. Follow-up was done for one year. RESULTS: During the year of follow-up, 19 patients (8.1%) of the overall cohort, developed seizures: 12 of them (12.6%) belonged to the control group and 7 (5%) to the study group p < 0.05). Results showed a decrease in the risk for developing seizure when treated with r-tpA, comparing to antiaggregants (odds ratio = 0.64). CONCLUSION: This study suggests there is an association between r-tPA treatment and reduction of the risk for post stroke seizures.
PURPOSE: Post stroke seizures are a complication that occur in 5-20% of acute ischemic stroke (AIS) patients, cause a reduction in quality of life and a greater burden on the health system. There is not enough data regarding an association between today's standard of care treatment in AIS: recombinant tissue plasminogen activator (r-tPA) and the risk for post stroke seizures. Our aim in this work is to reveal such a connection. METHOD: A non-randomized retrospective cohort-controlled study of 234 patients, who were hospitalized with acute ischemic stroke at Kaplan Medical Center in the years 2009-2015 and were divided into two different treatment groups: r-tPA and antiaggregant therapy(n = 141) and antiaggregant therapy only (n = 95) was conducted by us. Information regarding demographics, medical history, nature of the event, including NIHSS values on admission, discharge, and post stroke seizures, were obtained for each group. Follow-up was done for one year. RESULTS: During the year of follow-up, 19 patients (8.1%) of the overall cohort, developed seizures: 12 of them (12.6%) belonged to the control group and 7 (5%) to the study group p < 0.05). Results showed a decrease in the risk for developing seizure when treated with r-tpA, comparing to antiaggregants (odds ratio = 0.64). CONCLUSION: This study suggests there is an association between r-tPA treatment and reduction of the risk for post stroke seizures.
Authors: Lindsey R Kuohn; Alison L Herman; Alexandria L Soto; Stacy C Brown; Emily J Gilmore; Lawrence J Hirsch; Charles C Matouk; Kevin N Sheth; Jennifer A Kim Journal: J Stroke Cerebrovasc Dis Date: 2021-10-21 Impact factor: 2.136
Authors: Johann Philipp Zöllner; Björn Misselwitz; Thomas Mauroschat; Christian Roth; Helmuth Steinmetz; Felix Rosenow; Adam Strzelczyk Journal: Sci Rep Date: 2020-12-03 Impact factor: 4.379
Authors: Johann Philipp Zöllner; Friedhelm C Schmitt; Felix Rosenow; Konstantin Kohlhase; Alexander Seiler; Adam Strzelczyk; Hermann Stefan Journal: Neurol Res Pract Date: 2021-12-06